Harvard Bioscience (HBIO) Inventory Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Inventory Average data on file, last reported at $21.5 million in Q1 2026.

• On a quarterly basis, Inventory Average fell 6.62% year-over-year to $21.5 million in Q1 2026; TTM through Mar 2026 was $21.5 million, a 6.62% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 8.15% from the prior year.
• Inventory Average for Q1 2026 stood at $21.5 million, up from $21.2 million in the prior quarter.
• Over the last five years, Inventory Average for HBIO reached as high as $29.0 million in Q2 2022 and fell as low as $21.2 million in Q4 2025.
• Historically, Inventory Average has averaged $25.0 million across 5 years, with a median of $25.3 million in 2023.
• Across the five-year window, Inventory Average rose 25.28% in 2022 and dropped 14.2% in 2025, its largest moves.
• Year by year, Inventory Average stood at $26.3 million in 2022, then retreated by 3.85% to $25.3 million in 2023, then decreased by 2.57% to $24.6 million in 2024, then decreased by 13.86% to $21.2 million in 2025, then gained by 1.42% to $21.5 million in 2026.
• Per Business Quant data, the three most recent Inventory Average figures were $21.5 million in Q1 2026, $21.2 million in Q4 2025, and $21.9 million in Q3 2025.